![Recent progress in Ti3C2Tx-based materials: From fundamentals to emerging applications - ScienceDirect Recent progress in Ti3C2Tx-based materials: From fundamentals to emerging applications - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1369800122003742-ga1.jpg)
Recent progress in Ti3C2Tx-based materials: From fundamentals to emerging applications - ScienceDirect
![Impaired ion homeostasis as a possible associate factor in mucopolysaccharidosis pathogenesis: transcriptomic, cellular and animal studies | SpringerLink Impaired ion homeostasis as a possible associate factor in mucopolysaccharidosis pathogenesis: transcriptomic, cellular and animal studies | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11011-021-00892-4/MediaObjects/11011_2021_892_Fig2_HTML.png)
Impaired ion homeostasis as a possible associate factor in mucopolysaccharidosis pathogenesis: transcriptomic, cellular and animal studies | SpringerLink
![Tissue Imaging by Mass Spectrometry: A Practical Guide for the Medicinal Chemist | ACS Medicinal Chemistry Letters Tissue Imaging by Mass Spectrometry: A Practical Guide for the Medicinal Chemist | ACS Medicinal Chemistry Letters](https://pubs.acs.org/cms/10.1021/acsmedchemlett.8b00480/asset/images/medium/ml-2018-00480f_0002.gif)
Tissue Imaging by Mass Spectrometry: A Practical Guide for the Medicinal Chemist | ACS Medicinal Chemistry Letters
![VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles | NEJM VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2018/nejm_2018.379.issue-17/nejmoa1807120/20181024/images/img_small/nejmoa1807120_f1.jpeg)
VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles | NEJM
![VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles | NEJM VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2018/nejm_2018.379.issue-17/nejmoa1807119/20181024/images/img_medium/nejmoa1807119_f2.jpeg)
VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles | NEJM
![VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles | NEJM VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2018/nejm_2018.379.issue-17/nejmoa1807120/20181024/images/img_medium/nejmoa1807120_f1.jpeg)